Profile data is unavailable for this security.
About the company
Opus Genetics, Inc., formerly Ocuphire Pharma, Inc., is a clinical-stage ophthalmic biopharmaceutical company. The Company is engaged in developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. Its pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. Its most advanced gene therapy program is designed to address mutations in the LCA5 gene, which encodes the lebercilin protein and being evaluated in a Phase I/II open-label, dose-escalation trial, with advancing early data. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.
- Revenue in USD (TTM)16.45m
- Net income in USD-14.11m
- Incorporated2005
- Employees14.00
- LocationOpus Genetics Inc37000 Grand River Ave., Suite 120FARMINGTON HILLS 48335United StatesUSA
- Phone+1 (248) 681-9815
- Fax+1 (240) 268-5310
- Websitehttps://www.ocuphire.com/
More ▼
Mergers & acquisitions
| Acquired company | IRD:NAQ since announced | Transaction value |
|---|---|---|
| Opus Genetics Inc | -12.78% | 6.98m |
Data delayed at least 15 minutes, as of Nov 06 2024 18:23 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tonix Pharmaceuticals Holding Corp | 12.46m | -149.01m | 25.34m | 103.00 | -- | 0.0331 | -- | 2.03 | -110.99 | -110.99 | 6.16 | 4.28 | 0.1083 | 0.8436 | -- | 120,951.50 | -129.55 | -59.46 | -157.22 | -65.92 | 21.59 | -- | -1,196.12 | -5,126.73 | 0.7181 | -- | 0.1678 | -- | -- | -- | 0.1874 | -- | 320.57 | -- |
| BioXcel Therapeutics Inc | 2.40m | -107.83m | 27.58m | 74.00 | -- | -- | -- | 11.48 | -3.56 | -3.56 | 0.074 | -1.84 | 0.0234 | 0.5941 | 3.87 | 32,472.97 | -104.93 | -74.57 | -150.29 | -84.06 | 43.07 | -- | -4,487.39 | -32,300.74 | 2.25 | -10.10 | 3.59 | -- | 268.00 | -- | -8.02 | -- | -43.26 | -- |
| Natural Alternatives International, Inc. | 113.80m | -7.22m | 27.58m | 296.00 | -- | 0.334 | -- | 0.2424 | -1.23 | -1.23 | 19.38 | 13.32 | 0.7676 | 3.96 | 9.52 | 384,445.90 | -4.87 | 2.33 | -5.61 | 2.80 | 6.03 | 14.24 | -6.34 | 2.06 | 1.59 | -10.21 | 0.1326 | 0.00 | -26.11 | -3.82 | -386.16 | -- | -10.75 | -- |
| KALA BIO Inc | 0.00 | -38.72m | 30.87m | 43.00 | -- | 2.25 | -- | -- | -13.95 | -13.95 | 0.00 | 2.98 | 0.00 | -- | -- | 0.00 | -60.45 | -57.83 | -78.16 | -69.32 | -- | 57.06 | -- | -1,553.61 | -- | -11.36 | 0.7174 | -- | -100.00 | -- | 5.85 | -- | -17.31 | -- |
| Verrica Pharmaceuticals Inc | 9.21m | -84.99m | 34.03m | 100.00 | -- | -- | -- | 3.69 | -1.83 | -1.83 | 0.1979 | -0.798 | 0.1416 | -- | -- | 92,100.00 | -130.68 | -55.75 | -143.20 | -78.33 | 74.08 | -- | -922.81 | -754.94 | -- | -10.20 | -- | -- | -43.27 | -- | -173.59 | -- | 5.65 | -- |
| Dare Bioscience Inc | 2.84m | -7.20m | 34.51m | 23.00 | -- | 12.70 | -- | 12.15 | -1.07 | -1.07 | 0.3579 | 0.3126 | 0.1213 | -- | 3.85 | 123,462.20 | -30.76 | -109.51 | -191.39 | -246.26 | 0.8477 | -- | -253.60 | -1,104.55 | -- | -- | 0.00 | -- | -71.92 | -- | 2.54 | -- | 121.37 | -- |
| Opus Genetics Inc | 16.45m | -14.11m | 36.62m | 14.00 | -- | 0.7448 | -- | 2.23 | -0.5507 | -0.5507 | 0.6871 | 1.56 | 0.3726 | -- | 6.53 | 1,174,929.00 | -31.95 | -58.31 | -36.01 | -65.94 | -- | -- | -85.75 | -137.92 | -- | -10.80 | 0.00 | -- | -52.20 | -- | -155.83 | -- | -- | -- |
| Lexaria Bioscience Corp | 411.01k | -4.85m | 38.92m | 5.00 | -- | 3.48 | -- | 94.69 | -0.4455 | -0.4455 | 0.0408 | 0.6403 | 0.0539 | -- | 2.16 | 82,202.00 | -63.85 | -95.67 | -65.93 | -96.58 | 98.83 | 76.98 | -1,185.15 | -1,612.76 | -- | -64.96 | 0.00 | -- | -11.43 | -12.19 | 8.31 | -- | -- | -- |
| Incannex Healthcare Inc | 12.00k | -18.46m | 42.34m | 9.00 | -- | 3.40 | -- | 3,528.57 | -1.14 | -1.14 | 0.0007 | 0.7067 | 0.0003 | -- | 0.0024 | 1,333.33 | -48.51 | -130.12 | -54.36 | -148.24 | -- | -- | -153,833.30 | -3,421.98 | -- | -- | 0.00 | -- | -- | 61.03 | 62.18 | -- | 73.79 | -- |
| Eyenovia Inc | 31.41k | -37.28m | 43.86m | 57.00 | -- | -- | -- | 1,396.43 | -0.7897 | -0.7897 | 0.0007 | -0.0425 | 0.0013 | -- | 0.0418 | 551.05 | -154.24 | -80.31 | -262.28 | -117.70 | -1,489.11 | -- | -118,693.60 | -680.95 | 0.267 | -40.92 | 1.20 | -- | -- | -- | 2.68 | -- | 152.20 | -- |
| Earth Science Tech Inc | 20.30m | 1.98m | 43.89m | 32.00 | 22.22 | 13.86 | 20.46 | 2.16 | 0.0064 | 0.0064 | 0.0658 | 0.0103 | 5.40 | 36.44 | -- | 634,456.90 | 52.57 | -37.98 | 77.89 | -- | 69.40 | 63.87 | 9.74 | -15.48 | 1.24 | 3.57 | 0.0261 | -- | 24,526.37 | 73.03 | 322.25 | -- | -- | -- |
| Immix Biopharma Inc | 0.00 | -19.02m | 43.92m | 14.00 | -- | 1.84 | -- | -- | -0.8411 | -0.8411 | 0.00 | 0.871 | 0.00 | -- | -- | 0.00 | -86.64 | -- | -100.82 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -87.44 | -- | -- | -- |
| Fortress Biotech Inc | 82.62m | -49.54m | 48.65m | 186.00 | -- | 2.23 | -- | 0.5888 | -3.71 | -3.71 | 6.05 | 0.7915 | 0.5063 | 2.36 | 6.07 | 444,215.10 | -65.90 | -52.50 | -113.69 | -99.46 | 68.77 | 63.17 | -130.17 | -236.94 | 1.24 | -13.40 | 1.26 | -- | 11.58 | 25.75 | 27.42 | -- | -9.37 | -- |
Data as of Nov 06 2024. Currency figures normalised to Opus Genetics Inc's reporting currency: US Dollar USD
7.67%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 30 Jun 2024 | 986.41k | 3.77% |
| Geode Capital Management LLCas of 30 Jun 2024 | 265.85k | 1.02% |
| Richmond Brothers, Inc.as of 30 Jun 2024 | 191.30k | 0.73% |
| Bridgeway Capital Management LLCas of 30 Jun 2024 | 163.74k | 0.63% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 100.50k | 0.38% |
| Knoll Capital Management LPas of 30 Jun 2024 | 100.00k | 0.38% |
| SSgA Funds Management, Inc.as of 30 Jun 2024 | 70.47k | 0.27% |
| G1 Execution Services LLCas of 30 Jun 2024 | 46.58k | 0.18% |
| Jane Street Capital LLCas of 30 Jun 2024 | 42.38k | 0.16% |
| Kestra Private Wealth Services LLCas of 30 Jun 2024 | 42.34k | 0.16% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
